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Background: Although aspirin is effective in the secondary prevention of stroke among
men and women, its use in primary prevention remains controversial. We conducted a
meta-analysis of randomized trials to evaluate the benefit and safety of aspirin for the
primary prevention of ischemic stroke.
Methods: We searched three electronic databases (Medline, the Cochrane Central
Register of Controlled Trials, and Embase) for articles published before August 1st, 2016.
Randomized trials reporting the effect of aspirin on the primary prevention of ischemic
stroke and its side effects (hemorrhagic stroke and severe gastrointestinal bleeding) were
included. We used a fixed-effect model to quantify the effect of aspirin on the primary
prevention of stroke when the heterogeneity was low, or else applied the random-effect
model.
Results: Fourteen randomized trials were included. Overall, aspirin use was associated
with a decreased risk of ischemic stroke compared with non-aspirin use (OR: 0.83, 95%
CI: 0.74–0.93, P = 0.45). In subgroup analyses, the effect of aspirin on ischemic stroke
in apparently healthy adults remained significant (OR: 0.83, 95% confidence interval:
0.74–0.94, I2 = 22%, P = 0.28); while in patients with cardiovascular diseases there
was no difference in the risk of ischemic stroke between aspirin and non-aspirin groups
(OR: 0.75, 95% confidence interval: 0.44–1.29, P = 0.46). As for adverse effects, the
prophylactic use of aspirin potentially increased the risk of serious bleeding events in a
population of apparently healthy individuals and in patients with previous cardiovascular
diseases.
Conclusion: This meta-analysis of randomized trials indicated that both the apparently
healthy adults and patients with cardiovascular diseases will derive little protective benefit
from aspirin considering the increased risk of severe bleeding events.
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INTRODUCTION
The use of aspirin for the prevention of stroke is already fairly
widely spread in many communities. Although it is effective in
the secondary prevention of stroke among men and women,
its use in primary prevention remains controversial (Cuzick
et al., 2015; Kuznar and Uchiyama, 2015; Kwok et al., 2015).
The most recent AHA (American Heart Association) guideline
for the primary prevention of cardiovascular disease and stroke
recommends the use of aspirin in persons whose 10-year risk
for coronary heart disease is 6–10% to improve the likelihood
of a positive balance of coronary risk reduction over bleeding
and hemorrhagic stroke caused by aspirin. It also suggests
aspirin is not useful for preventing a first stroke in person at
low risk (Goldstein et al., 2011). Thus, the use of aspirin for
cardiovascular (including but not specific to stroke) prophylaxis
is recommended for persons whose risk is sufficiently high for
the benefits to outweigh the risks associated with treatment.
Since these recommendations, each patient should undergo
an assessment of stroke risk to determine who might benefit
from therapeutic interventions. Although independent stroke
predictors such as age, hypertension, and diabetes mellitus are
identified, an ideal stroke risk-assessment tool that is generally
applicable, simple and widely accepted does not exist, making the
use of aspirin for preventing a first stroke in persons at elevated
risk extremely ambiguous (Chobanian et al., 2003; Kissela et al.,
2005; Sturgeon et al., 2007).
Recent systematic analysis of the outcomes from the nine
randomized controlled trials confirmed that aspirin had no
statistically significant effect on stroke (Bartolucci et al., 2011).
However, the included primary prevention trials compared the
incidence of all strokes. The reduction in occlusive events might
be offset by any increase in cerebral bleeds since the prophylactic
use of aspirin could potentially increase the risk of hemorrhagic
stroke (Sato et al., 2006; Paciaroni et al., 2007). Under that
circumstance, harm from cerebral bleeds might outweigh the
benefit from aspirin. Meanwhile, there was another possible
explanation for the conclusion that aspirin had no statistically
significant effect on stroke: aspirin failed to protect ischemic
stroke and didn’t increase the risk of hemorrhagic stroke as
well. The effects of aspirin on ischemic stroke and hemorrhagic
stroke needed to be evaluated respectively. The reasons were
as follows: if aspirin had no significant effects on both strokes,
then it was not recommended for prevention of stroke but could
still be prescribed to prevent other cardiovascular events such
as coronary heart disease. If aspirin increased the risk of major
bleeds (although it decreased the incidence of ischemic stroke),
then it would be avoided for the prevention of stroke and should
be prescribed with great caution to prevent other cardiovascular
diseases.
In addition, it has been found that aspirin has differential
effects in distinct populations. The previous meta-analysis
investigating the effect of low-dose aspirin on the primary
prevention of stroke included nine clinical trials, which enrolled
both patients with previous cardiovascular events and apparently
healthy volunteers. Numerous studies found the overall benefit
of aspirin is confined to those with low pressures while men with
pressures ofmore than 145mmHgwill derive little cardiovascular
protective benefit from aspirin (Meade and Brennan, 2000).
In patients with type 2 diabetes, low-dose aspirin as primary
prevention did not reduce the risk of ischemic stroke (Ogawa
et al., 2008). The results of US trial raised the possibility that
aspirin may have been more effective in those aged 50 years
or more and when cholesterol concentrations were low rather
than high (Steering Committee of the Physicians’ Health Study
Research Group, 1989). For healthy individuals, aspirin may have
only a modest effect as a primary prevention of stroke (Baigent
et al., 2009). Thus, an important concern in the previous meta-
analysis was confounding by factors associated with the stroke
types and type of people studied. In this meta-analysis, we aimed
to compare the effects of aspirin on the incidence of ischemic
stroke and hemorrhagic stroke respectively, and hope to identify
a higher-risk group who might derive substantial benefit from
aspirin therapy.
METHODS
Literature Search and Study Selection
We attempted to identify all randomized controlled trials that
evaluated aspirin treatment as compared with a control (placebo
or no aspirin), that included data on the incidence of stroke and
adverse events, and that were published on or before August
1st, 2016. We conducted searches of Medline, the Cochrane
Central Register of Controlled Trials, and Embase. There were
no language limitations for the initial search. Cohort studies
and case-control studies were excluded. All the included studies
required patients provided written informed consent. Key words
used to search for relevant publications included the following:
(“aspirin” and “stroke”) or (“aspirin” and “prevention”).
Data Extraction
Titles and abstracts of the articles were screened by two reviewers
(Hong Lei and Qian Gao) independently. Included articles
for full text screening were compared during a consensus
meeting. In case of disagreement, a third reviewer (Jian Xu) was
consulted for the decision on inclusion or exclusion for full-
text evaluation. Articles that did not contribute to the answer of
our research questions after full text evaluation were excluded.
After consensus the remaining articles were included for critical
appraisal and assessed by two reviewers independently. Articles
(RCT studies) were judged on scientific quality according to the
CONSORT and STROBE statement (von Elm et al., 2007; Schulz
et al., 2010).
Data Analysis and Statistical Methods
The significance of the combined odds ratio (OR) was
determined by the Z-test, in which P < 0.05 was considered
significant. The χ2-based Q statistical test was used for
the assessment of the between-study heterogeneity, which
was considered significant for P < 0.1. In analyses, if the
heterogeneity was low, then we used a fixed-effect model,
or else applied the random-effect model. Software of Review
Manager 5.3 was used to perform the meta-analyses (available
from Cochrane). When the heterogeneity was high, we collected
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sufficient information to conduct particular subgroup analyses to
determine the population-aspirin interaction and stroke types-
aspirin interaction. As the number of trials was small (≤10), a
funnel plot was not used to assess publication bias.
RESULTS
Figure 1 shows the selective process after the search: Of the 14
included articles in this systematic review, a total of 8 studies
enrolled patients with previous cardiovascular events and 7
studies enrolled volunteers with or without increased risk for
cardiovascular diseases (Peto et al., 1988; Steering Committee
of the Physicians’ Health Study Research Group, 1989; Lindblad
et al., 1993; Hansson et al., 1998; The Medical Research Council’s
General Practice Research Framework, 1998; Cook et al., 2000;
Meade and Brennan, 2000; de Gaetano, 2001; Sacco et al., 2003;
Cleland et al., 2004; Ridker et al., 2005; Ogawa et al., 2008;
Fowkes et al., 2010; Kurth et al., 2011). The risk factors included:
FIGURE 1 | Flow diagram of selected studies.
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old age (≥65 years), hypertension, hypercholesterolemia, obesity,
diabetes, and family history of premature myocardial infarction.
Characteristics of the Studies
The characteristics of the included articles are reported inTable 1
(see below).
A summary of study quality indicators is presented in Table 2.
Randomization occurred in all 14 studies, but only 5 studies
described the process of random sequence generation (Peto et al.,
1988; The Medical Research Council’s General Practice Research
Framework, 1998; de Gaetano, 2001; Sacco et al., 2003; Ogawa
et al., 2008). The use of allocation concealment was clearly
stated only in three of the trials (The Medical Research Council’s
General Practice Research Framework, 1998; Cook et al., 2000;
de Gaetano, 2001). All studies had a Jadad score of three or
greater except one. Five trials were open-labeled (Peto et al.,
1988; de Gaetano, 2001; Sacco et al., 2003; Cleland et al., 2004;
Ogawa et al., 2008). Loss to follow-up was accounted for in all
trials. None of the trials appeared to have substantial baseline
differences between patients allocated to aspirin therapy vs. the
comparator-arm.
Primary Prevention of All Stroke and
Ischemic Stroke with Aspirin
A total of 10 studies reported on the efficacy of aspirin in primary
prevention of all strokes in people with or without cardiovascular
risk factors (Steering Committee of the Physicians’ Health Study
Research Group, 1989; Lindblad et al., 1993; Hansson et al.,
1998; The Medical Research Council’s General Practice Research
Framework, 1998; Meade and Brennan, 2000; de Gaetano, 2001;
Sacco et al., 2003; Cleland et al., 2004; Ridker et al., 2005; Fowkes
et al., 2010). When compared with those not taking aspirin, all
included studies didn’t show any difference in the incidence of
TABLE 1 | Characteristics of 14 studies included in the review.
Study Studied population Participants (n) Control (n) Ischemic stroke
(Participants/
Control)
Severe adverse events
Hemorrhagic
stroke
(Participants/
Control)
Gastrointestinal
bleeds
(Participants/
Control)
Ogawa et al. (2008)8 Patients with diabetes 81–100mg aspirin daily
(1262)
No aspirin (1277) 23/29 5/3 4/0
Ridker et al. (2005)13 Women 100mg aspirin on
alternate days (19,934)
100mg placebo on
alternate days
(19,942)
170/221 51/41 127/91
Meade and Brennan
(2000)7
Men with increased risk of
coronary heart disease
75mg aspirin daily (8105) 75mg placebo daily
(8071)
NA NA NA
Fowkes et al. (2010)14 Elderly people (50–75 years) 100mg aspirin daily
(1675)
100mg placebo daily
(1675)
44/50 5/5 9/8
Sacco et al. (2003)15 Patients with diabetes; Patients
without diabetes
100mg aspirin daily (519);
100mg aspirin daily
(1875);
No aspirin (512), No
aspirin (1893)
NA NA NA
Cook et al. (2000)16 Elderly people (40–84 years) 325mg aspirin on
alternate days (11,010)
325mg placebo on
alternate days (3849)
110/42 NA NA
Kurth et al. (2011)17 Women (≥45 years) 100mg aspirin on
alternate days (19,869)
100mg placebo on
alternate days
(19,888)
170/221 51/41 NA
Peto et al. (1988)18 Male doctors 500mg aspirin daily
(3429)
No aspirin (1710) NA 1/0 NA
Lindblad et al. (1993)19 Patients undergoing carotid
endarterectomy
75mg aspirin daily (117) 75mg placebo daily
(115)
NA NA NA
Cleland et al. (2004)20 Patients with heart failure 300mg aspirin daily (91) No aspirin (89) NA NA NA
Hansson et al. (1998)21 Patients with increased blood
pressure
75mg aspirin daily (9399) 75mg placebo daily
(9391)
NA NA NA
The Medical Research
Council’s General Practice
Research Framework
(1998)22
Patients with increased risk for
ischemic heart disease
75mg aspirin daily (1268) 75mg placebo daily
(1272)
1/3 2/0 6/2
de Gaetano (2001)23 Patients with increased risk for
cardiovascular disease
100mg aspirin daily
(2226)
No aspirin (2269) NA 2/0 NA
Steering Committee of the
Physicians’ Health Study
Research Group (1989)9
Healthy male physicians 325mg aspirin on
alternate days (11,037)
325mg placebo on
alternate days
(11,034)
91/82 23/12 NA
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TABLE 2 | Summary of quality indicators for studies assessing aspirin for the primary prevention of stroke.
Study, Year Random
sequence
generation
Allocation
concealment
Blinding of
participants and
outcome-assessors
Placebo-
controlled
Lost to follow up
accounted
Potential
baseline
difference
JADAD
score
(Range 0–5)
Ogawa et al. (2008)8 Yes No No No Yes No 3
Ridker et al. (2005)13 No No Yes Yes Yes No 4
Meade and Brennan (2000)7 No No Yes Yes Yes No 4
Fowkes et al. (2010)14 No No Yes Yes Yes No 4
Sacco et al. (2003)15 Yes No No No Yes No 3
Cook et al. (2000)16 No Yes Yes Yes Yes No 4
Kurth et al. (2011)17 No No Yes Yes Yes No 4
Peto et al. (1988)18 Yes No No No Yes No 3
Lindblad et al. (1993)19 No No Yes Yes Yes No 4
Cleland et al. (2004)20 No No No No Yes No 2
Hansson et al. (1998)21 No No Yes Yes Yes No 4
The Medical Research Council’s
General Practice Research
Framework (1998)22
Yes Yes Yes Yes Yes No 5
de Gaetano (2001)23 Yes Yes No No Yes No 4
Steering Committee of the
Physicians’ Health Study
Research Group (1989)9
No No Yes Yes Yes No 4
stroke in people taking aspirin. Meta-analysis of these 10 studies
resulted in a pooled OR of 0.93, 95% CI 0.83–1.04, indicating no
benefit of aspirin in primary prevention of stroke of any kind
(Figure 2A).
A total of seven studies reported on the efficacy of aspirin in
primary prevention of ischemic stroke (Steering Committee of
the Physicians’ Health Study Research Group, 1989; The Medical
Research Council’s General Practice Research Framework, 1998;
Cook et al., 2000; Ridker et al., 2005; Ogawa et al., 2008;
Fowkes et al., 2010; Kurth et al., 2011). When compared with
person not taking aspirin, two large randomized clinical trials
demonstrated a decreased risk of stroke in people taking aspirin
(Ridker et al., 2005; Kurth et al., 2011). Another five studies
didn’t show any difference in the incidence of ischemic stroke
(Steering Committee of the Physicians’ Health Study Research
Group, 1989; The Medical Research Council’s General Practice
Research Framework, 1998; Cook et al., 2000; Ogawa et al., 2008;
Fowkes et al., 2010). Meta-analysis of these seven studies resulted
in a pooled OR of 0.83, 95% CI 0.74–0.93, indicating a mild but
significant reduction in the incidence of ischemic stroke in those
taking aspirin (Figure 2B).
Since aspirin may have a differential effect on different
population, we therefore examined two subgroups: people
without cardiovascular diseases; people with cardiovascular
diseases such as diabetes and hypertension. A total of five studies
reported on the efficacy of aspirin in primary prevention of
ischemic stroke among people without cardiovascular diseases
(Steering Committee of the Physicians’ Health Study Research
Group, 1989; Cook et al., 2000; Ridker et al., 2005; Fowkes et al.,
2010; Kurth et al., 2011). Two large randomized clinical trials
demonstrated a decreased risk of ischemic stroke in people taking
aspirin (Ridker et al., 2005; Kurth et al., 2011), while another three
studies didn’t show any difference in the incidence of ischemic
stroke (Steering Committee of the Physicians’ Health Study
Research Group, 1989; Cook et al., 2000; Fowkes et al., 2010).
Meta-analysis of these five studies resulted in a pooled OR of 0.83,
95% CI 0.74–0.94, indicating a mild but significant reduction in
the incidence of ischemic stroke in those relatively healthy person
taking aspirin (Figure 2C). Another two studies demonstrated
the effect of aspirin on people with cardiovascular diseases
(The Medical Research Council’s General Practice Research
Framework, 1998; Ogawa et al., 2008). Meta-analysis of these
two studies resulted in a pooled OR of 0.75, 95% CI 0.44–1.29,
indicating no benefit of aspirin in prevention of ischemic stroke
in people with cardiovascular diseases (Figure 2D).
The Risk of Hemorrhagic Stroke after
Exposure to Aspirin
A total of nine studies reported on the incidence of hemorrhagic
stroke after exposure to aspirin (Peto et al., 1988; Steering
Committee of the Physicians’ Health Study Research Group,
1989; Hansson et al., 1998; The Medical Research Council’s
General Practice Research Framework, 1998; de Gaetano, 2001;
Ridker et al., 2005; Ogawa et al., 2008; Fowkes et al., 2010; Kurth
et al., 2011). There were 154 episodes of hemorrhagic stroke in the
aspirin group, as compared with 116 in the placebo (no aspirin)
group. Meta-analysis of these nine studies resulted in a pooled
OR of 1.32, 95% CI 1.04–1.68, indicating an increased risk of
hemorrhagic stroke in people taking aspirin (Figure 3A).
There was some evidence that the value of aspirin might vary
with blood pressure and serum glucose. We therefore examined
two subgroups: people without cardiovascular diseases; people
with cardiovascular diseases such as diabetes and hypertension.
In relatively healthy population, there is an increased risk of
hemorrhagic stroke in the aspirin group as compared with the
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FIGURE 2 | Primary prevention of all stroke (A) and ischemic stroke (B–D) with aspirin. Results were presented for all individuals combined (B), apparently healthy
individuals (C) and individuals without cardiovascular diseases (D).
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FIGURE 3 | The risk of hemorrhagic stroke after treatment with aspirin. Forrest plot of fixed effect meta-analysis for pooled ORs of hemorrhagic stroke. Results
were presented for all individuals combined (A), apparently healthy individuals (B), and individuals without cardiovascular diseases (C).
placebo (no aspirin) group. The pooled OR was 1.35 (95% CI
1.05–1.75) (Figure 3B). In patients with cardiovascular diseases,
there was no significant difference between aspirin and placebo
(no aspirin) for the risk of hemorrhagic stroke. The pooled OR
was 1.12 (95% CI 0.58–2.16) (Figure 3C).
The Risk of Major Gastrointestinal Bleeds
after Exposure to Aspirin
A total of five studies reported on the incidence of major
gastrointestinal bleeds after exposure to aspirin (The Medical
Research Council’s General Practice Research Framework, 1998;
Hansson et al., 1998; Ridker et al., 2005; Ogawa et al., 2008;
Fowkes et al., 2010). There were 223 episodes of major
gastrointestinal bleeds in the aspirin group, as compared with
138 in the placebo (no aspirin) group. Meta-analysis of these
five studies resulted in a pooled OR of 1.62, 95% CI 1.31–2.00,
indicating an increased risk of major gastrointestinal bleeds in
people taking aspirin (Figure 4A).
We then examined whether patients with cardiovascular
diseases were at a greater risk of developing major
gastrointestinal bleeds. In relatively healthy population, there is
an increased risk of major gastrointestinal bleeds in the aspirin
group as compared with the placebo (no aspirin) group. The
pooled OR was 1.41 (95% CI 1.09–1.82) (Figure 4B). In patients
with cardiovascular diseases, there was a significantly increased
risk of major gastrointestinal bleeds in the aspirin group as
compared with the placebo group (no aspirin). The pooled OR
was 2.18 (95% CI 1.48–3.22) (Figure 4C) (see below).
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FIGURE 4 | The risk of severe gastrointestinal bleeds after treatment with aspirin. Forrest plot of fixed effect meta-analysis for pooled ORs of serious
gastrointestinal bleeds. Results were presented for all individuals combined (A), apparently healthy individuals (B), and individuals without cardiovascular diseases (C).
DISCUSSION
When evaluating the effects of aspirin on ischemic stroke
and hemorrhagic stroke respectively, our results indicated a
significant 17 percent reduction in the risk of ischemic stroke
and a significant 32 percent increase in the risk of hemorrhagic
stroke, which suggested a net increase in the risk of hemorrhagic
stroke in the study populations. This finding was particularly
relevant, since under most circumstances, aspirin was prescribed
to prevent ischemic cardiovascular events while actually the
prophylactic use of aspirin might only provide limited protection
against ischemic stroke. The harm from cerebral bleeds exceeded
the benefit among those taking aspirin.
Numerous studies suggested the hypothesis that low-dose
aspirin might be less effective in patients with cardiovascular
diseases as compared with the general population. Although
heterogeneity of trial results was low (I2 = 0%), we divided the
studied populations into two groups: those with cardiovascular
disease (such as diabetes, dyslipidemia, and hypertension) and
those with not. Our results demonstrated that the positive
effects of aspirin remained significant in the general population
while patients with previous cardiovascular events seemed to
derive little benefit from aspirin. Several mechanisms have been
suggested that can be responsible for these findings. As for
diabetes, it has been suggested that the involvement of aspirin
insensitive Cox-2, as an additional source of TxA2, contributed
to aspirin resistance (Halushka and Halushka, 2002). Thus,
in patients with diabetes, platelets could be activated through
different mechanisms that can lead to thrombosis despite aspirin
therapy. As for hypercholesterolemia, a lower effect of aspirin in
the presence of elevated values of total cholesterol was described
in the Physician’s Healthy Study and the Thrombosis Prevention
Trial (Steering Committee of the Physicians’ Health Study
Research Group, 1989; The Medical Research Council’s General
Practice Research Framework, 1998). It has been shown that
the increasing level of cholesterol was associated with reduced
responsiveness of platelets to aspirin (Friend et al., 2003). As
for hypertension, it has often been considered a contradiction
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to aspirin because of the concern that possible benefits in the
prevention of occlusive events may be counterbalanced by an
increased risk of cerebral bleeding (Hansson et al., 1998).
For patients who would experience severe adverse events such
as hemorrhagic stroke after prophylaxis use of aspirin, aspirin
was more likely to do harm than good. To our knowledge, severe
adverse events related to aspirin included hemorrhagic stroke
and major bleeds. The latter included serious bleeding from any
tissue or organ. The most common one was gastrointestinal
bleeding. Usually, patients who had serious gastrointestinal
bleeding needed transfusion. Thus, in our study, we compared
the risk of hemorrhagic stroke and severe gastrointestinal bleeds
between the aspirin and no aspirin groups. Overall, these side
effects were more common in the aspirin group than in the
non-aspirin group. We then conducted particular subgroup
analyses to determine whether aspirin could both increase the
risk of serious adverse events in two different populations. Our
findings showed that in the general population, aspirin increased
the risk of specific adverse events such as hemorrhagic stroke
and severe gastrointestinal bleeding. While in patients with
cardiovascular diseases, aspirin use was only associated with
a significant increase in the risk of severe gastrointestinal
bleeding. It had no significant effect on hemorrhagic
stroke.
These findings indicated that the benefit of aspirin was offset
by the risk of bleeding in general population. In patients with
cardiovascular diseases, aspirin failed to decrease the incidence
of ischemic stroke, instead, it increased the risk of severe
gastrointestinal bleeding. To our knowledge, Self-medication
with aspirin is widespread, especially by many for whom there is
increased risk of developing cardiovascular diseases. If our results
are correct, patients with cardiovascular diseases will derive little
protective benefit from aspirin. They will, however, be exposed
to the risk of troublesome and serious bleeding. There might be
no good for recommending aspirin use for apparently healthy
person as well. Physicians should not be afraid to do nothing
when there is no evidence that treatment is effective and clear
evidence that it has side effects.
We acknowledge several limitations of our study. Firstly,
we were only able to incorporate a total of three trials in our
analyses to study the benefit and safety of aspirin in patients with
cardiovascular diseases. Although there was no heterogeneity
between studies, the small number of included trials reduced
the statistical power. Thus, these findings must be interpreted
with great caution. More randomized clinical trials for specific
populations were needed to illustrate the benefit and harm of
aspirin in the primary prevention of ischemic stroke among
patients with cardiovascular diseases. Secondly, not all the
included studies were double-blinded, randomized, controlled
trials, a total of five studies were open, randomized clinical
trials. Finally, most of the patients from the included studies
were of Caucasian descent, suggesting a limited confidence when
applying this data to other populations.
CONCLUSIONS
This meta-analysis of randomized trials indicated that both
the apparently healthy adults and patients with cardiovascular
diseases will derive little protective benefit from aspirin
considering the increased risk of severe bleeding events.
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